GRAIL presents PATHFINDER 2 results at ASCO

GRAIL said full results from its PATHFINDER 2 study, presented Sunday at the 2026 ASCO Annual Meeting, showed that its Galleri blood test increased cancer detection 6.5-fold compared with recommended screening alone.

The company said the study included 35,878 participants and reported a positive predictive value of 60.3%, an episode sensitivity of 69.8% for the 12 cancers responsible for two-thirds of U.S. cancer deaths, and a false positive rate below 0.4%.

According to GRAIL, the median time to diagnostic resolution was 48 days. The company also said invasive procedures followed positive results in 0.6% of safety-analyzable participants.

What GRAIL said

GRAIL described the PATHFINDER 2 findings as showing robust performance and favorable safety for the Galleri test, which is designed to screen for multiple cancers from a blood sample.

The company said the results were drawn from the full cohort of more than 35,000 participants and were presented as an oral abstract at ASCO.

The release did not include independent commentary or external validation of the findings.

Why it matters

Multi-cancer early detection tests remain an active area of clinical research because they aim to identify cancers before symptoms appear and potentially before they become harder to treat.

PATHFINDER 2 is one of the larger public readouts for Galleri to date, and the company is using the ASCO stage to highlight both detection performance and safety metrics.

The results may draw investor and clinician attention because they add fuller data to an earlier presentation announcement and come alongside broader questions about how blood-based cancer screening will fit into routine care.

GRAIL did not identify any conflicting claims in its announcement.